Extreme diversity of the major surface antigen and virulence determinant of the malaria parasite Plasmodium falciparum, Erythrocyte Membrane Protein-1 (PfEMP1), poses a major barrier to identifying targets of protective immunity. To overcome this problem, we developed a PfEMP1 protein microarray containing 456 DBLα domains, which was used to characterize the immunome of a cohort of semi-immune children and to identify variants associated with protective immune responses. Children with high mean antibody levels to DBLα group 2 had a 26-36% reduced risk of uncomplicated (clinical) malaria, however only 8 diverse DBLα variants were weakly associated with protection from clinical malaria and had low predictive accuracy. On the other hand, children with high mean antibodies to DBLα groups 1 and 2 (which are markers for pathogenic "Type A" PfEMP1) and elevated antibodies to 85 (18.6%) of individual DBLα variants had a 70 -100% reduced risk of severe malaria. Of the top 20 predictive variants for severe disease protection, 17 were strongly associated with protection (86 -100% reduction in risk of severe malaria) and had high predictive accuracy for severe disease risk. Many variants were conserved and had highly correlated antibody responses, including the three highest-ranking variants, which were linked to EPCR-binding CIDR domains. The results suggest that while immunity to uncomplicated malaria is characterised by antibodies to a diverse repertoire of PfEMP1, immunity to severe malaria requires antibodies to a limited subset of antigenically conserved variants. These findings provide new insights into antimalarial immunity and potential biomarkers for tracking disease risk.
Introduction
Antigenic diversity of human pathogens is critical for evasion of host immune responses and is a significant challenge for the development of vaccines and other interventions.
Human malaria parasites employ this strategy to achieve super-infection and to re-infect previously exposed hosts (1, 2). In addition, they utilize clonal antigenic variation to persist within hosts and maximize transmission potential (3) . Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1), expressed on the surface of infected erythrocytes, is the dominant target of naturally acquired immunity to malaria (4) . To evade immune responses, parasites switch PfEMP1 variants through differential expression of distinct members of the var multigene family (5) (6) (7) . PfEMP1 plays a key role in parasite virulence via cytoadhesion of infected erythrocytes to various host cell receptors (8) . Naturally acquired immunity develops with frequent exposure to P. falciparum infections, and is thought to require the piecemeal acquisition of antibodies to distinct PfEMP1 variants circulating in the parasite population (9) . This immunity is non-sterilizing and presents as a reduction in the severity of malaria symptoms with age (9, 10) . The acquisition of immunity to severe malaria early in life after only a small number of infections (11) suggests that clinically important PfEMP1 are antigenically conserved, whereas immunity against mild disease develops more slowly and may require a broader repertoire of antibodies to diverse PfEMP1 variants. Defining these immune targets is a key priority for the development of interventions to reduce the burden of malaria, including vaccines and biomarkers of exposure (12) .
A major hurdle to overcome in the identification of clinically important PfEMP1 variants is the extreme genetic diversity of the multicopy var genes that encode these antigens (13) (14) (15) , and a lack of appropriate tools to consider the full spectrum of diversity. Each P. falciparum genome harbors up to 60 distinct var genes with high levels of sequence diversity both within and between genomes (16) . The Duffy Binding Like alpha (DBLα) domains present within the relatively conserved head structure of almost all var genes have been used as a marker for var gene diversity and gene expression studies (14, (23) (24) (25) (26) (27) . In order to extrapolate these findings to full length var genes with diverse functions, short (150-200 amino acid residue) DBLα sequence tags have been classified into six subgroups based on the number of cysteine residues (Cys2, Cys4, CysX) and specific sequence motifs (MFK and REY) in positions of limited variability (Cys/PoLV, (17, 18) ), whilst full length DBLα domains have been classified into 3 subgroups (DBLα0, 1, 2) based on evolutionary relationships (19) . Group 1-3 DBLα tags (Cys2) are found in group A var genes and are expressed at high levels in parasites infecting young children with limited immunity and with severe disease (20) (21) (22) . DBLα groups 4-6 (Cys4/X) account for the majority of the sequences from non-group A var genes (23) . Expression of group 1 DBLα (Cys2 MFK+REY-) is associated with impaired consciousness and cerebral malaria (21, 22) , whilst expression of group 2 DBLα (Cys2 MFK-REY+) and group 5 DBLα (Cys4 MFK-REY+) has been associated with rosetting and severe malarial anaemia (17, 24) .
Interestingly, groups 1 and 2 are also more conserved than other DBLα classes (17) .
DBLα also plays a direct role in cytoadhesion (25) and anti-DBLα antibodies disrupt rosettes, reduce parasite cytoadhesion and are associated with clinical immunity in hyperendemic regions (26, 27) . Antibody responses to recombinant DBLα tags may therefore reveal exposure to associated full-length, clinically significant, var gene classes.
Anti-DBLα antibodies also have potential as biomarkers of immunity against malaria and may directly confer protective immunity, however no link between antibodies to specific subgroups or individual variants and clinical or severe malaria has been made to date.
Clinical or severe malaria-associated PfEMP1 variants have potential as targets of malaria interventions, however identifying the most important variants amongst the thousands circulating in natural parasite populations (13, 14, (28) (29) (30) requires novel approaches. We sought to investigate antibody responses using parasite-encoded DBLα domains and human plasma derived from semi-immune children naturally exposed to these parasites, to address key questions about immunity to PfEMP1 including: i) which recombinant PfEMP1 domains are recognized broadly by naturally acquired antibodies, ii) are these antibodies protective against clinical and severe malaria, and iii) how conserved are key antibody targets (12) . In order to identify PfEMP1 variants that are key targets of immunity against severe and clinical disease, we developed a protein microarray containing 456 distinct DBLα variants to represent the PfEMP1 (var gene) diversity in the Papua New Guinea (PNG) parasite population (14) . Using this array, we seroprofiled PNG children aged 1-3 years old that were followed prospectively for clinical and severe malaria, allowing associations to be measured between the DBLα antibody repertoire and risk of disease.
Candidate DBLα variants were then matched to identify corresponding full-length var genes composition in the PNG parasite population. The results provide key insights into the early acquisition of antibody responses to PfEMP1, identify biomarkers and potential targets of protection against clinical and severe malaria, and exposes links between the genetic and antigenic diversity of PfEMP1 that are critical to its development as a vaccine candidate.
Results

DBLα protein microarray design and quality control
We developed a protein microarray representing the var gene diversity of three parasite populations of PNG (Fig. S1) . Validation of the protein array is described in the Materials and Methods and in the Supporting Material (Text S1, Fig. S2 ). After quality control, which included resequencing, successful cloning into the expression vector and checking for high quality protein spots on the array, antibody data from 456 DBLα sequences were included in the analyses (Text S1, Fig. S1, S2 ). This includes 42 group 1 (Cys2 MFK+REY-), 10 group 2 (Cys2 MFK-REY+), 32 group 3 (Cys2 MFK-REY-), 278 group 4 (Cys4 MFK-REY-), 63 group 5 (Cys4 MFK-REY+) and 31 group 6 (CysX, MFK-REY-) variants. This reflects the proportions found among 4656 full length DBLα domains extracted from 4656 var genes assembled using whole genome sequence (WGS) data from 122 independent PNG isolates as we described previously ((31), Fig. S1 ). Group 2 DBLα variants were underrepresented on the protein microarray relative to the WGS data (2.2% vs 4.7%, p = 0.008) (Fig. 1A) , which may be due to primer bias or the lower diversity of this subgroup (17) .
To further evaluate the diversity of DBLα using the PNG WGS data, we compared the distribution of DBLα classes among the alternative DBLα classes (19) and association with CIDR domain classes. Of note, groups 1, 2 and 3 DBLα variants were found within DBLα1.1-1.8 domains, which are associated with the upsA promoter of type A var genes (19, 32) . These groups are also associated with Endothelial Protein C Receptor (EPCR) binding (e.g. CIDR1) and rosetting-associated CIDR domains (CIDRb/d/g) (32) . In addition, DBLα2, a type B var gene domain associated with CIDRα1.1/1.8 in DC8 head structures (19) , were largely composed of group 2 (33%) and 3 (43%) DBLα variants (Fig. 1) .
Therefore, the developed protein microarray is the most comprehensive protein array to date representing the genetic and functional diversity of DBLα domains found in naturally circulating parasite populations. PNG children (aged 1-3, n=25) showed moderate reactivity, and PNG adults (n=20) had overall high reactivity to the different DBLα variants ( Fig. 2A, Fig S3) . Antibody profiles of individual children showed differential recognition of DBLα variants (Fig. 2B) . By stratifying the antibody response data according to the six DBLα subgroups, we found that group 1 and group 2 variants were more frequently recognized (p < 0.0001), while antibody levels to groups 3-6 were generally low (Fig. 2C) . The sero-dominance of group 1 and 2 variants was evident across all ages in the cohort (Fig. 2D) .
We hypothesized that if exposure to the DBLα variants circulating in an endemic area increases with age and repeated exposure to infection, then the overall antibody response will increase in magnitude (mean antibody titre) and breadth (mean number of antigens recognized). In an initial exploratory analysis, DBLα antibodies were associated with age (antibody level, p = 0.014; breadth, p = 0.002) and concurrent infection (p < 0.0001), as well as average exposure as predicted by the number of infections during the follow-up period (molecular force of blood stage infection, mol FOB, p < 0.0001, Fig S5) (34) . Overall antibody level significantly increased with age (Pearson's r = 0.24, p = 0.0002), mol FOB (Pearson's r = 0.29, p < 0.0001) and "life-time" exposure (age scaled by mol FOB, Pearson's r = 0.38, p < 0.0001) (Fig. 2E) .
Due to the complex interaction of age and mol FOB with magnitude and breadth of antibody response ( Fig. 2F) of the variability in the breadth of antibody response, whereas age only 25% [95% CI: 6.5
-52], which suggests that in these children mol FOB explains the differences in the antibody levels more accurately than age. Thus, we are in a unique position to accurately assess the association of antibody responses with prospective risk of severe and clinical malaria after correcting each child's antibody response for the key confounders of age and mol FOB. Antibody levels averaged for the six DBLα subgroups showed high responders to group 1 and group 2 DBLα variants had a 100% reduced risk compared to low responders ( 4C) . A neighbour joining tree shows that the majority of the protective variants are from a relatively conserved clade, which correspond to variants from type "A" var genes (13), however there were also diverse protective variants outside this clade (Fig. S5) . compared to the non-severe cases (p < 0.0001), but there was no significant difference in antibody responses to non-protective variants. By the end of the follow-up period, after an average of 6 six infections per child, antibody levels to all variants and specifically to those protective variants were boosted (p < 0.0001). No significant difference in antibody response was observed in non-severe cases for the protective variants, but there was a significant increase for the non-protective variants (p = 0.0002) (Fig. 5) . 
Antibodies to protective DBLα variants predict prospective risk of severe but not clinical malaria
The lack of antibody responses to protective variants in young children who developed severe malaria and boosting of these antibody responses by the end of the follow-up period suggests that certain PfEMP1 antibodies may be a useful predictor for future risk of severe malaria. To test this hypothesis, we built a data driven machine-learning model to identify predictive variants. The top 20 variants, based on the mean decrease in classifier accuracy, were selected for further analyses (Table S1 ). Of these, 17 were significantly associated with protection (86 -100% reduction in risk of severe malaria) in the analysis above, therefore we focused all further analysis on these variants (Table S2 ). The 17
variants included representatives from all 6 DBLα sub-groups, however group 1 variants were dominant (41%, p<0.0001, exact binomial test). Furthermore, at enrolment, antibody levels to the 17 variants were significantly lower in severe cases compared to non-severe cases (p < 0.0001, Fig. S6 ), and were boosted by the end of the follow-up period (Fig.S6) , despite the lack of difference in force of infection between the two groups.
In order to evaluate the predictive utility of antibodies in discriminating between children who go on to experience severe malaria and those who do not, receiver operating characteristic curves (ROC) were generated and the area under the curves (AUC) determined. The AUC is associated with high predictive accuracy when its value is close to 1. Antibodies against the top 17 protective and predictive DBLα variants had high predictive accuracy (median AUC = 0.82 [range: 0.66 -0.88]) (Fig. 6A, Table S2 ). Three variants, WOS_026 (sub-groups 3 and DBLα2), WOS_025 (sub-groups 1 and DBLα1.1) and WOS_068 (sub-groups 1 and DBLα1.1) variants, had the highest AUC 0.88, 0.86 and 0.83 and are associated with 100% reduction in risk of severe malaria (Table S2) . AME_1620 (sub-groups 4 and DBLα0.2) variant, had the lowest AUC (0.66) and the lowest incidence rate ratio (aIRR = 0.17) of the top 17 DBLα variants (Table S2) . When averaged by DBLα subgroup, group 1 and group 2 DBLα variants had high predictive values (AUC ≥ 0.8), while all the other groups had low discriminatory power for prediction of severe malaria (Fig. 6B ). This demonstrates that low antibody levels against DBLα groups 1 and 2 are predictive of prospective risk of severe malaria. However, antibody levels to any of the individual DBLα variants or subgroups had a poor predictive power for clinical malaria (AUC= 0.5 -0.57). In fact, mol FOB was the major predictor of clinical malaria (AUC=0.8) but this was not the case for severe malaria (AUC= 0.49), and is consistent with previous findings (34) (Fig. S7) . Table S2 . The red dashed diagonal line represents the ROC curve for a test with no discriminatory ability (AUC=0.5).
Discussion
The diversity of PfEMP1 poses a formidable obstacle to the study of naturally acquired Protection against severe malaria however was strongly associated (up to 100% reduced risk) with high mean antibodies to both group 1 and 2 DBLα and 85 individual variants (enriched for group 1 and 2 DBLα variants). At the end of the follow-up period antibodies to these 85 severe-disease protective variants were significantly higher, indicating that these antibodies were acquired through natural infection as the children were exposed in average to six new infection during the follow-up period. Furthermore, we identified the top 20 highly predictive variants through machine learning, revealing that low antibodies to 17 Children develop protective antibodies specific to the infecting parasite isolate following infection (4) and these antibodies are thought to provide subsequent protection from heterologous isolates (4, (36) (37) (38) (39) . Associations of antibodies to specific PfEMP1 variants with protection from severe and clinical malaria could be obscured by the confounding effects of cumulative exposure due to the high diversity and immunogenicity of PfEMP1 (12) . In this study, we were able to adjust for the confounding effects of individual exposure reduced risk of severe malaria. This is the first study that has shown a strong association of antibody responses with specific PfEMP1 variants and protection against severe malaria. This implies that PfEMP1 containing these DBLα subgroups are important targets (or co-expressed with important targets), of immunity against severe malaria.
Exploring the dynamics of variant-specific antibody responses in the children who experienced severe malaria revealed significantly lower levels of antibodies to all DBLα groups compared to other children, suggesting that low levels of PfEMP1 antibodies in general may be associated with susceptibility. The strong associations of antibodies to DBLα groups 1, 2 and 3 (Cys2) and protection from severe malaria suggest that children with high levels of antibodies to these groups may be able to control disease and are protected from severe malaria. This is supported by the negative correlation of expression of these groups with anti-VSA antibodies in another study (18) . Children with severe malaria had significantly lower levels of antibodies to the protective variants before the onset of severe malaria. These antibodies were significantly boosted during the severe malaria episode and remained high in the convalescent period. Our analysis of the predictive accuracy of low antibodies to group 1 and 2 DBLα variants, as well as the top 17 predictive and protective variants for severe malaria, suggests they may be developed as biomarkers for antimalarial immunity against severe disease. These biomarkers would be extremely useful to identify high-risk human populations in regions attempting to eliminate malaria.
Our results suggest that a broad repertoire of antibodies is important for protection against clinical malaria. Nevertheless, mean antibodies to group 2 DBLα variants reduced the risk of clinical, and high-density clinical malaria. Previous studies showed that elevated expression of group 2 variants is associated with rosetting and severe malaria (18, 20-22, 28, 40) . In addition, we previously found group 2 to be serodominant in PNG infants less than one year of age, consistent with these variants being expressed in early infections (13) . The association of group 2 antibodies with a reduced risk of clinical episodes represents a major advance in defining and limiting the subset of PfEMP1 containing these domains as functional immune targets and warrants further investigation, because group 2 variants account only for 2 to 10% of the total DBLα variants sampled so far in several geographic areas (13, 14, 17, 20, 29, (40) (41) (42) .
There is a strong rationale for a PfEMP1 vaccine that would protect against clinical and severe malaria, since any reduction in disease and death would ease the huge burden of malaria infection on susceptible individuals (43) . Leading candidates to protect against severe malaria include specific classes of PfEMP1 variants and domain cassettes (DCs) that have been linked to the pathogenesis of severe malaria through in vivo and in vitro expression studies (12) . These include VAR2CSA [also known as DC2 (44)], DC4, DC8
and DC13 (45) (46) (47) (48) (49) , which are shared by majority of the P. falciparum clones analyzed (20) and exhibit conserved features linked to cytoadhesion (50) . Recent studies have also demonstrated functional and structural conservation of the highly diverse CIDR domain (51) (52) (53) , however no conserved epitopes have yet been identified in naturally circulating parasite populations. In the same cohort studied here, antibodies to ICAM-1 binding DBLβ domains were associated with protection against clinical malaria and the predicted ICAM1-binding DBLβ PfEMP1 were enriched for DC4 and DC13 head-structures, previously implicated in severe malaria (31) . In the current study, analysis of full-length var gene sequences from PNG isolates showed group 1 and 2 DBLα variants were strongly associated with DC4 and DC13 type CIDR domains. As these variants were also associated with protection, this suggests conservation of these domain cassettes and multiple binding specificities (52. 53) . Despite the extreme global diversity of var genes, the data presented herein links antibody responses against PfEMP1 variants previously implicated in severe malaria with strong protection from severe malaria. These variants are overrepresented by group 1 variants, the most conserved DBLα variants found exclusively in Type A var genes (17) . To pursue PfEMP1 antigens as viable vaccine candidates, it will be critical to define the antigenic diversity of leading candidates, and to assess whether immune responses to geographically diverse PfEMP1s are associated with protection from clinical and severe malaria in multiple endemic areas. The use of high-throughput technologies, such as protein microarrays that we have employed here, together with welldesigned cohort studies will be essential for this task. 
Materials and Methods
Ethics Statement
Study Area and Samples
The PNG north coast is an area of perennial high transmission of P. falciparum malaria (53) . Plasma samples were collected in a longitudinal cohort survey conducted in Ilaita area in the East Sepik Province of PNG in 2006 (33) . Briefly, 264 children aged 1-3 years of age (median 1.70 years) were enrolled and followed for 69 weeks. The study consisted of three fortnightly surveillance visits and each concluding with the collection of two blood samples 24 hours apart for active detection of malaria infection. Incidence of clinical malaria in each 8-9 week follow-up interval was estimated as previously described (31, 33) . Clinical malaria was defined as febrile illness (axillary temperature ≥37.5°C or history of fever in preceding 48 hrs) with a concurrent P. falciparum parasitemia >2500
parasites/µl. High-density clinical malaria was defined as febrile illness with a concurrent P. falciparum parasitemia >10000 parasites/µl. Infection and mol FOB was determined using light microscopy and PCR (31, 33) . The DBLα variants were amplified from genomic DNA (Fig. S1 ).
The details of these studies are published elsewhere (13, 14) .
Protein microarray production, validation and serological screening
Protein microarray chips were constructed as described previously (56) (57) (58) (59) (60) (61) . Protein arrays were used to probe 3μl of plasma samples diluted in 1:100 protein array-blocking buffer (Maine Manufacturing) with 20% (w/v) E. coli lysate, which significantly reduced the background as compared to the conventional 10% (w/v) E. coli lysate (p < 0.0001, Wilcoxon rank sum test) (Fig. S2A) . Therefore, in all assays 20% (w/v) E. coli lysate in blocking buffer was used. Antibody assays were performed using paired plasma samples collected at enrolment and end of the follow-up from 232 children. The assays were done as described previously (56) (57) (58) (59) (60) (61) . The proportion of DBLα groups represented on the protein array and the relationship between DBL and CIDR domains groupings were compared in 4656 DBLα and 6142 CIDR sequences obtained from 122 whole genome PNG sequences (31) .
Data processing and normalization
Signal intensities were corrected for spot-specific background, where the per-spot local background was subtracted. The SI (Signal Intensity) was normalized against the "No DNA" controls using the variance stabilization and normalization method and using the VSN package installed in R-project (62) . The vsn-normalized data was used for all statistical analyses and visualization (mean intensity in log2).
The antibody responses to the DBLα variants were quantified using three measurements: function of the total number tested (% DBLα variants recognized). The DBLα variants on the array were grouped in to six (Group 1 to 6) as described previously (17) . The average magnitude, breadth and seroprevalence were calculated according to these classifications. was assessed using linear regression and relative importance was determined using the R package 'relaimpo' using the R 2 partitioned by averaging over orders and the results were bootstrapped to determine 95% confidence intervals as described previously (63) . The exact binomial test was used to test for a biased distribution of subgroups amongst protective antigens.
Statistical analysis
A negative binomial GEE model (based on XTNBREG procedure in STATA 12.0) was used for the analysis of incidence of clinical and severe P. falciparum malaria. The R package 'randomForest' was used to build random forest binary classifiers in order to assess antibodies to which variants predict the prospective risk of severe or clinical malaria (64) . We used out-of-bag (OOB) error rate to measure the performance of the model. Out-of-bag error rate stabilized at 2,000 trees, so we chose this as a parameter for optimizing the number of variants sampled per node, which was determined as mtry = 3.
The predictor variants were then evaluated based on the variable of importance. These 
